Hepatic arterial infusion chemotherapy versus transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma:a comparative study
10.3969/j.issn.1008-794X.2024.05.015
- VernacularTitle:经肝动脉灌注化疗或化疗栓塞术联合酪氨酸激酶抑制剂及卡瑞利珠单抗治疗不可切除肝细胞癌的对比研究
- Author:
Luhao CHEN
1
;
Yi YANG
;
Jingwen ZHANG
;
Qi LIU
;
Junrong LU
;
Yingwen HOU
;
Yan LIU
Author Information
1. 150006 黑龙江哈尔滨 哈尔滨医科大学附属肿瘤医院介入科
- Keywords:
hepatocellular carcinoma;
hepatic arterial infusion chemotherapy;
transcatheter arterial chemoembolization;
tyrosine kinase inhibitor;
immunotherapy;
combination therapy
- From:
Journal of Interventional Radiology
2024;33(5):543-548
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the efficacy and safety of transarterial chemoembolization(TACE)and hepatic arterial infusion chemotherapy(HAIC)combined with tyrosine kinase inhibitors(TKI)and immune checkpoint inhibitors(ICI)for advanced hepatocellular carcinoma(HCC).Methods A total of 101 patients with unresectable HCC,who were admitted to the Affiliated Cancer Hospital of Harbin Medical University of China between January 2021 and October 2022 to receive treatment,were enrolled in this study.Of the 101 patients,50 received TACE+TKI+ICI therapy(TACE+TKI+ICI group)and 51 received HAIC+TKI+ICI therapy(HAIC+TKI+ICI group).The overall survival(OS)and the progression-free survival(PFS)were compared between the two groups,and the adverse events were analyzed to assess the safety of the therapeutic scheme.Results The median PFS in the TACE+TKI+ICI group was 12.0 months,which in the HAIC+TKI+ICI group was 11.0 months(P=0.030).The median OS was not achieved in the TACE+TKI+ICI group,which in the HAIC+TKI+ICI group was 14.6 months(P=0.005).The most common adverse effects in the TACE+TKI+ICI group were the elevation of total bilirubin(46.0％)and hepatic function injury(26.0％),which in the HAIC+TKI+ICI group were the decrease of albumin level(62.7％),fatigue(39.2％),and gastrointestinal reactions(31.4％).Conclusion For the treatment of advanced HCC,the therapeutic scheme of TACE+TKI+ICI has a better long-term survival benefits and the therapeutic scheme of HAIC+TKI+ICI can better maintain the liver function reserve of the patients.Neither therapeutic scheme shows any unexpected toxicity,and both therapeutic schemes have high clinical safety.(J Intervent Radiol,2024,33:543-548)
